IV formulation [Design Issues]

posted by Dr Andrew Leary – Ireland, 2010-05-21 12:21 (5876 d 02:28 ago) – Posting: # 5363
Views: 3,662

Hello Helmut

Good to see you in Ljubljana. As I've said before, keep fighting the good fight!

I've been asked to design a BE study for an IV formulation. It is expected that proof of BE will be required because of differences in how the formulation has been put together compared to reference. In my view (based on NO experience!), IV administration (in this case, a 1-hour infusion) should ensure very low intra-subject CVs for Cmax and AUC because BA will be 100% in all cases. This should allow for a small study (perhaps only 12 subjects) if all the other usual assumptions apply.

Do you concur, or is there something I'm missing?

Kind regards

Andrew

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
130 visitors (0 registered, 130 guests [including 18 identified bots]).
Forum time: 14:49 CEST (Europe/Vienna)

Scientists cannot simply hang their subjectivities
up on a hook outside the laboratory door.    Ruth Bleier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5